ClinicalTrials.Veeva

Menu

Emulated Study of Vitamin D Correction Vs Non-Correction

Cooper University Health Care logo

Cooper University Health Care

Status

Active, not recruiting

Conditions

Vitamin D Deficiency

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

  • This is a single-site retrospective electronic chart review of Cooper Health System Inpatients and Outpatients from 2008 through 2023 aged eighteen years or older. This review is designed as an emulation of a randomized clinical trial with a nonrandomized database.
  • The primary objectives are to compare healthcare costs and healthcare utilization between subjects who have corrected low vitamin D levels and those without corrected low vitamin D levels.

Full description

  • The purpose of the study is to characterize healthcare costs and healthcare utilization in subjects with corrected low (<40 ng/ml) 25-OH vitamin D levels compared to subjects with uncorrected low 25-OH vitamin D levels during a three-year period.
  • The primary objective of this study is to determine whether ten healthcare costs are lower and ten healthcare utilization parameters occur less frequently in patients with corrected low vitamin D levels compared to patients with uncorrected low vitamin D levels in Cooper outpatients and inpatients.

The costs are:

  1. total billed costs for any reason;
  2. total billed costs for hospitalizations;
  3. total billed costs for ICU admissions;
  4. total billed costs for emergency room visits;
  5. total billed costs for all other outpatient services;
  6. total billed costs for urgent care visits;
  7. total billed costs for primary care physician (PCP) services;
  8. total billed costs for nurse practitioner (NP) services;
  9. total billed costs for all other professional services;
  10. total billed costs for medical pharmacy services and products.

The parameters are:

  1. number of hospitalizations for any reason;

  2. number of ICU admissions for any reason;

  3. number of emergency room visits for any reason;

  4. all other outpatient services for any reason;

  5. number of urgent care visits for any reason;

  6. number of primary care physician visits for any reason;

  7. number of nurse practitioner visits for any reason;

  8. all other professional services for any reason;

  9. number of medical pharmacy services for any reason;

  10. number of free-standing prescriptions for any reason.

    • The secondary objective is to determine the effect of sufficient vitamin D levels (≥ 40 ng/ml) in subjects not requiring a prior correction on the ten healthcare costs parameters and the ten healthcare utilization parameters listed in the primary objective above.

Enrollment

9,000 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Any patient with at least one 25-OH vitamin D test result. Patients with one test result will remain in the limited dataset for potential future research.
  • Any patient with a 25-OH vitamin D level(s) always lower than 40 ng/ml (low level) with subsequent level(s) in the 40 ng/ml to 100 ng/ml range. The 40 ng/ml to 100 ng/ml range is maintained for three years. This corrected group is labeled as the Treatment Group.
  • Any patient with a 25-OH vitamin D level always lower than 40 ng/ml with maintenance of that lower than 40 ng/ml level for 3 years. This uncorrected group is labeled as Control Group A.
  • Any patient who has an uninterrupted 25-OH vitamin D level greater than or equal 40 ng/ml and less than or equal to 100 ng/ml (sufficient level) for a continuous 3-year period. Prior to the 3-year period there were no levels lower than 40ng/ml or higher than 100 ng/ml. This vitamin D3 sufficient group is labeled as Control Group B.

Exclusion criteria

  • Any patient with only one 25-OH vitamin D3 test result or any patient who cannot be included in the Treatment Group, Control Group A, or Control Group B is excluded.

Trial design

9,000 participants in 3 patient groups

Treatment Group
Description:
Any patient with a 25-OH vitamin D level(s) always lower than 40 ng/ml (low level) with subsequent level(s) in the 40 ng/ml to 100 ng/ml range. The 40 ng/ml to 100 ng/ml range is maintained for three years.
Control Group A
Description:
Any patient with a 25-OH vitamin D level always lower than 40 ng/ml with maintenance of that lower than 40 ng/ml level for 3 years.
Control Group B
Description:
Any patient who has an uninterrupted 25-OH vitamin D level greater than or equal 40 ng/ml and less than or equal to 100 ng/ml (sufficient level) for a continuous 3-year period. Prior to the 3-year period there were no levels lower than 40ng/ml or higher than 100 ng/ml.

Trial contacts and locations

1

Loading...

Central trial contact

Principal Investigator; Investigator

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems